Cover Image
市場調查報告書

神經學生物標記的全球市場:2016∼2020年

Global Neurological Biomarkers Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 370817
出版日期 內容資訊 英文 68 Pages
訂單完成後即時交付
價格
Back to Top
神經學生物標記的全球市場:2016∼2020年 Global Neurological Biomarkers Market 2016-2020
出版日期: 2016年09月08日 內容資訊: 英文 68 Pages
簡介

生物標記是為了鑑定特定疾病的指標,識別病情發展,識別藥物標的之有效的手段。神經疾病的特定相關生物標記被稱作神經學生物標記。全球神經學生物標記市場,預計到2020年以15.48%的年複合成長率擴大。

本報告提供全球神經學生物標記市場相關調查,市場現狀與成長預測,各地區趨勢,及主要供應商簡介彙整。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 神經學生物標記的全球市場:市場情況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第6章 神經學生物標記的全球市場:各適應症市場區隔

  • AD
  • PD
  • ASD
  • MS

第7章 神經學生物標記的全球市場:各用途市場市場區隔

  • 基因學
  • 蛋白質體學
  • 代謝體學
  • 影像
  • 新興用途

第8章 神經學生物標記的全球市場:各類服務市場區隔

第9章 神經學生物標記的全球市場:各終端用戶市場區隔

  • 醫院
  • 診斷、研究實驗室

第10章 神經學生物標記的全球市場:各地區市場區隔

  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區

第11章 神經學生物標記的全球市場:促進要素

第12章 促進要素的影響

第13章 神經學生物標記的全球市場:課題

第14章 促進要素與課題的影響

第15章 神經學生物標記的全球市場:趨勢

第16章 供應商環境

  • 競爭模式

第17章 主要供應商分析

  • 各地區據點
  • Myriad RBM
  • Proteome Sciences
  • QIAGEN
  • Thermo Fisher Scientific
  • 其他值得注意的供應商

第18章 附錄

第19章 關於Technavio

目錄
Product Code: IRTNTR10239

About Biomarkers

Biomarkers are the indicators considered for identifying specific diseases. They are mainly used for identification of the progress of a particular disease and evaluation of an effective method for drug target identification. The biomarkers specifically involved in the identification of the neurological disorders are called neurological biomarkers.

Technavio's analysts forecast the global neurological biomarkers market to grow at a CAGR of 15.48% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global neurological biomarkers market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of neurological biomarkers.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Neurological Biomarkers Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Myriad RBM
  • Proteome Sciences
  • QIAGEN
  • Thermo Fisher Scientific

Other Prominent Vendors

  • AbaStar MDx
  • Abiant
  • Acumen Pharmaceuticals
  • Aepodia
  • Alseres Pharmaceuticals
  • Athena Diagnostics
  • Banyan Biomarkers
  • Cisbio Bioassays
  • Diagenic
  • Proteosys
  • Psynova Neurotech

Market driver

  • Increasing focus toward drug discovery applications
  • For a full, detailed list, view our report

Market challenge

  • Unmet market needs of effective validation of biomarkers
  • For a full, detailed list, view our report

Market trend

  • Integrated biology approach will be the key focus area
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights
  • Biomarker assays kits

PART 05: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis:

PART 06: Market segmentation by indication

  • AD
  • PD
  • ASD
  • MS

PART 07: Market segmentation by application

  • Genomics-based biomarkers
  • Proteomics-based biomarkers
  • Metabolomics-based biomarkers
  • Imaging-based biomarkers
  • Emerging application areas

PART 08: Market segmentation by services

  • Services

PART 09: Market segmentation by end-user

  • Hospitals
  • Diagnostic and research laboratories

PART 10: Geographical segmentation

  • Neurological biomarkers market in Americas
  • Neurological biomarkers market in EMEA
  • Neurological biomarkers market in APAC

PART 11: Market drivers

  • Increasing low-cost clinical trials in developing countries
  • Growing personalized medicine for neurological disorders
  • Increasing focus toward drug discovery applications

PART 12: Impact of drivers

PART 13: Market challenges

  • Unmet market needs of effective validation of biomarkers
  • Reproducibility of biomarkers and tests leading to discrepancies
  • Delay in market launch

PART 14: Impact of drivers and challenges

PART 15: Market trends

  • Integrated biology approach will be the key focus area
  • Development of novel radiotracers for neuro biomarkers that aid diagnostic and clinical applications for diseases
  • Evolution of miRNA

PART 16: Vendor landscape

  • Competitive scenario

PART 17: Key vendor analysis

  • Geographic presence - Key vendor analysis
  • Myriad RBM
  • Proteome Sciences
  • QIAGEN
  • Thermo Fisher Scientific
  • Other prominent vendors

PART 18: Appendix

  • List of abbreviations

PART 19: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Key biomarker technology platforms
  • Exhibit 03: Global neurological biomarkers market (2016-2020) ($ billions)
  • Exhibit 04: Five forces analysis
  • Exhibit 05: Market segmentation by indication
  • Exhibit 06: Market opportunities in the major indications
  • Exhibit 07: Global neurological biomarkers market segmentation by application 2015
  • Exhibit 08: Market opportunities in key applications
  • Exhibit 09: Impact mapping of neurological biomarker services
  • Exhibit 10: Opportunity analysis of biomarker services
  • Exhibit 11: Global neurological biomarkers market 2015
  • Exhibit 12: Market overview in Americas 2015
  • Exhibit 13: Neurological biomarkers market in Americas ($ billions)
  • Exhibit 14: Market overview in EMEA 2015
  • Exhibit 15: Neurological biomarkers market in EMEA ($ billions)
  • Exhibit 16: Market overview in APAC 2015
  • Exhibit 17: Neurological biomarkers market in APAC ($ millions)
  • Exhibit 18: Impact of drivers
  • Exhibit 19: Impact of drivers and challenges
  • Exhibit 20: Competitive structure analysis of global neurological biomarkers market 2015
  • Exhibit 21: Market penetration of key neurological biomarkers manufacturers 2015
  • Exhibit 22: Strategic success factors of companies in global neurological biomarkers market
  • Exhibit 23: Regional analysis of key vendors
  • Exhibit 24: Myriad RBM: Profile
  • Exhibit 25: Myriad RBM: Strength analysis
  • Exhibit 26: Myriad RBM: Growth strategy matrix
  • Exhibit 27: Myriad RBM: Opportunity assessment analysis
  • Exhibit 28: Proteome Sciences: Profile
  • Exhibit 29: Proteome Sciences: Strength analysis
  • Exhibit 30: Proteome Sciences: Growth strategy matrix
  • Exhibit 31: Proteome Sciences: Opportunity assessment
  • Exhibit 32: QIAGEN: Profile
  • Exhibit 33: QIAGEN: Strength analysis
  • Exhibit 34: QIAGEN: Growth strategy matrix
  • Exhibit 35: QIAGEN: Opportunity assessment
  • Exhibit 36: Thermo Fisher Scientific: Profile
  • Exhibit 37: Thermo Fisher Scientific: Strength analysis
  • Exhibit 38: Thermo Fisher Scientific: Growth strategy matrix
  • Exhibit 39: Thermo Fisher Scientific: Growth opportunity assessment
Back to Top